De omzet in Amerika van Ruconest gaat niet integraal naar Pharming.
Zie voorwaarden Santarus. --> max. $45 miljoen kunnen ze per kalenderjaar krijgen.
under the license agreement, Pharming granted us the non-exclusive rights to develop and manufacture and the exclusive right to commercialize licensed products in the U.S., Canada and Mexico.
In partial consideration of the licenses granted under the license agreement, we paid Pharming a $15 million upfront fee and will be required to pay $5 mllion milstone upon FDA acceptance for review of a BLA for Rhucin. We may also be recuired to pay Pharming additional succes-based clinical and commercial milestones totaling up to an aggregate of $30million, including a $10 million milestone payable on successful completion of the phase III clinical study, depending upon the achievement of developmental and commercial objectives. In addition, we will be required to pay certain one-time performance milestones if we achieve certain aggregate net sales levels of Rhucin. The amount of each such milestone payment varies upon the level of net sales in a calender year. The maximum amount of all such payments to Pharming would be $45 million, assuming net sales exceeded $500 million in a calender year. As consideration for the licenses and rights granted under the license agreement, and as compensation for the commercial supply of Rhucin by Pharming pursuant to the supply agreement, we will pay Pharming a tiered supply price, based on a percentage of net sales of Rhucin, subject to reduction in certain events